More Stories

Informist, Friday, Aug. 14, 2026

 

Please click here to read all liners published on this story

--Ipca Lab: Logistics costs high Q2 amid shipment delays, container shortage 
--CONTEXT: Ipca Laboratories mgmt comments in post-earnings investor call 
--Ipca Lab: Chronic, acute therapy outpaced overall market growth 
--Ipca Lab: Raise FY27 revenue growth guidance to 14-16% 
--Ipca Lab: FY27 revenue growth to be led by generic, branded ops 
--Ipca Lab: Not seeing pressure on margins in Jul-Sept 
--Ipca Lab: May add 200 medical representatives in India ops soon 
--Ipca Lab: Brazil ops' margins turning positive, see further improvement 
--Ipca Lab: Raise FY27 EBITDA margin guidance to 23% 
--Ipca Lab: Europe, UK ops delivered healthy growth in Apr-Jun 
--Ipca Lab: Plan to expand capacity to cater demand in Europe, US mkts 
--Ipca Lab: To focus on capacity expansion, R&D, API facilities 
--Ipca Lab: Expect interest costs to decline in coming qtrs 
--Ipca Lab: Have seven products in pipeline for biotech ops 

 

By Gunjan Rajput and Ashutosh Pati

 

MUMBAI/NEW DELHI –  IPCA Laboratories Ltd. has raised its revenue growth guidance for financial year 2026-27 (Apr-Mar) to 14-16% from 12-13%, and the consolidated earnings before interest, tax, depreciation, and amortisation margin guidance to 23% from 22%. The company cited a better than expected performance across its businesses for the upward revisions, a top official said in a post-earnings investor call Friday.

 

"Overall growth...may become almost around 14 to 16% .. for the current financial year," the official said. The company expects growth in FY27 to be led by its generic and branded operations, with the India and active pharmaceutical ingredient businesses performing well. "Now look at the size what we are getting from overall generic business, India business performance very well, and API business has given good growth," the official said.

 

The company expects no margin pressure in Jul-Sept despite higher material and logistics costs. "No margin pressure," the official said, adding material cost as a percentage of sales is expected to ease slightly. 

 

Ipca Lab's consolidated net profit for the June quarter rose 72% to INR 4.02 billion from INR 2.33 billion in the year-ago quarter. Analysts had estimated the company's net profit at INR 3.10 billion. The company's consolidated revenue from operations was INR 27.88 billion, up 21% on year from INR 23.09 billion. Analysts had estimated the revenue from operations at INR 25.61 billion. The revenue growth was driven by broad-based growth across all segments.

 

 

Ipca Laboratories said logistics costs were higher in July and August as well, after rising in the June quarter, amid shipment delays and container shortages, with freight rates increasing across South America, the US, and Europe. "Everywhere, rates are moving up," the official said, adding that the higher costs have been factored into its guidance.

 

The company said both chronic and acute therapies in the domestic market outpaced overall market growth in Apr-Jun. Europe and UK markets delivered healthy growth during the quarter, while margins of Brazil operations have turned positive and are expected to improve further. "Both Europe and UK business both have done very well," the official said.

 

The company may add around 200 medical representatives to its India operations during the year to support new business launches.

 

Ipca Laboratories plans to expand capacity to cater to demand in European and US markets, while increasing investments in research and development and API facilities. "This is the capacity expansion will also be needed. And that's going on right now because we need a lot of capacity for European markets and US markets," the official said. He added that around INR 7 billion-INR 8 billion is expected to be spent on capex in FY27.

 

The company expects interest costs to decline in the coming quarters, with current debt at around INR 1.93 billion and no short-term borrowings. Ipca has around seven biotech products in its pipeline and plans to invest around INR 1 billion in biotech pilot facilities and research and development in FY27.

 

The company detailed its June quarter earnings on Thursday during market hours. On Friday, shares of the company ended at INR 1,734.20 on the National Stock Exchange, down 3.5% from Thursday.  End

 

Edited by Avishek Dutta

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (11) 4220-1000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.